Dermatology · Irvine, CA
NPI
1356390181
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
15374 Alton Pkwy
Irvine, CA, 92618
Phone (949) 552-4211
Groups this clinician bills Medicare through
Medicare paid, 2024
$166K
3,112 services
Medicare patients, 2024
452
Average age 75
Drug cost, 2024
$19.1M
3,589 prescriptions
Company payments, 2025
$483
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sergei Grando was code J3301 (injection, triamcinolone acetonide, not otherwise specified, 10 mg), 914 times for 75 patients. In total Sergei Grando billed 3,112 services in 27 codes, and Medicare paid $166K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-12-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 914 | 75 | $0.67 | $613 |
| 17003 Destruction Skin Lesion | Office | 356 | 63 | $5.97 | $2,124 |
| 99214 Office E&M - Established | Office | 301 | 188 | $113.32 | $34K |
| 99215 Office E&M - Established | Office | 249 | 79 | $153.05 | $38K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 228 | 81 | $14.03 | $3,199 |
| 96910 Skin | Office | 224 | 43 | $117.04 | $26K |
| 99213 Office E&M - Established | Office | 193 | 151 | $77.73 | $15K |
| 96372 Injection Administration | Office | 109 | 74 | $12.36 | $1,347 |
| 17000 Destruction Skin Lesion | Office | 105 | 80 | $48.13 | $5,053 |
| 17110 Destruction Skin Lesion | Office | 68 | 59 | $100.61 | $6,841 |
| 99203 Office E&M - New | Office | 55 | 55 | $90.89 | $4,999 |
| 99423 E&M - Miscellaneous | Office | 54 | 37 | $37.32 | $2,015 |
| 99204 Office E&M - New | Office | 48 | 48 | $144.66 | $6,944 |
| 17004 Destruction Skin Lesion | Office | 45 | 35 | $144.68 | $6,511 |
| 11102 Skin Biopsy | Office | 36 | 35 | $77.38 | $2,786 |
By year: 2022 $174K for 2,435 services; 2023 $138K for 2,023 services; 2024 $166K for 3,112 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sergei Grando prescribed most often to Medicare patients was Doxycycline Monohydrate, with 264 prescriptions and refills. In total Sergei Grando wrote 3,589 Medicare prescriptions that cost $19.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Doxycycline Monohydrate Generic | 264 | 328 | 53 | $9,239 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 263 | 274 | 28 | $4.5M |
| Mycophenolate Mofetil Generic | 230 | 361 | 64 | $31K |
| Clobetasol Propionate Generic | 213 | 232 | 117 | $13K |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 195 | 219 | 24 | $3.9M |
| Doxycycline Hyclate Generic | 173 | 203 | 38 | $3,182 |
| Prednisone Generic | 165 | 186 | 55 | $1,318 |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | 135 | 136 | 14 | $2.0M |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 111 | 122 | 16 | $2.3M |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 99 | 99 | 14 | $1.5M |
| Dupixent Pen Dupilumab | 94 | 94 | 22 | $382K |
| Cyclosporine Modified Cyclosporine, Modified | 78 | 107 | 20 | $14K |
| Sodium Chloride 0.9 % Sodium Chloride | 78 | 85 | 22 | $550 |
| Rituxan Rituximab | 77 | 87 | 12 | $464K |
| Triamcinolone Acetonide Generic | 67 | 72 | 42 | $513 |
Brand drugs: 1,461 claims; generic drugs: 2,128 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sergei Grando $483 ($483 in general payments such as food, travel and fees) from 1 company. The largest payer was BeiGene, Ltd. with $483.
| Company | Payments | Amount |
|---|---|---|
| BeiGene, Ltd. ONC | 1 | $483 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.